The RCSI Precision Cancer Medicine (PCM) group is concerned with the development of novel precision medicine approaches to treat cancer. We work to elucidate novel predictive biomarkers (genomic, transcriptomic, proteomic) and identify new therapeutic targets. The PCM group works primarily on colorectal and brain malignancies with an overall goal to improve patient outcomes.

To achieve our objectives, we employ highly disruptive multi-modality molecular imaging and Next Generation Sequencing (NGS) approaches. We have particular expertise implementing Patient Derived Xenografts (PDX) and other clinically relevant disease models.